newsfilter
← Latest News
PR Newswire·

New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

BIOA
  • BioArctic AB partner Eisai will present new clinical & real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London from July 12-15, 2026.
  • Presentations will cover data on lecanemab subcutaneous formulation, long-term use in diverse patient groups, maintenance dosing, & at-home administration.
  • BioArctic will participate in the July 14 Plenary Session discussing strategies for assessing clinical progression in people with cognitive impairment related to α-synuclein pathology, primarily across Parkinson's disease, Parkinson's disease dementia, & dementia with Lewy bodies.
  • Key oral presentations include emerging evidence on the subcutaneous formulation on July 12 & results from the LEADER study on July 14 evaluating real-world use three years post-approval.
  • The LEADER study presentation will include results on maintenance dosing with IV treatment every four weeks & first reported findings of at-home subcutaneous administration.
  • Phase 3 AHEAD 3-45 study presentations will highlight progress in preclinical Alzheimer's disease, including updates on participant retention & engagement.
  • Multiple poster presentations are scheduled for July 12-15 covering topics such as subcutaneous administration outcomes, patient satisfaction, economic impact, & safety data from various global regions including the US, Japan, Hong Kong, & China.
  • An Eisai-sponsored symposium for healthcare professionals titled "Early Intervention in Alzheimer's Disease: Building the Evidence from Pathology to Practice" is scheduled for July 14 from 12:30 – 1:45pm BST.
  • Leqembi is approved in 53 countries & under regulatory review in 6 countries as of June 30, 2026.
  • Intravenous maintenance dosing every four weeks is approved in 8 countries, including the UK, China, US, & Japan.
  • In the US, Leqembi Iqlik™ is approved for subcutaneous maintenance dosing with an autoinjector.
  • Eisai's supplemental Biologics License Application for a subcutaneous starting dose received Priority Review from the US FDA in January 2026 with an extended PDUFA date of August 24, 2026.
  • The subcutaneous formulation application was accepted for priority review in China in January 2026.
  • The AHEAD 3-45 Phase 3 study in preclinical Alzheimer's disease was fully recruited in October 2024 & is ongoing as a public-private partnership.
  • BioArctic holds commercial rights for lecanemab in the Nordic region & is entitled to sales milestones & royalties from global sales.
  • BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap.